A phase I study of KTN-0158 for the treatment of mast cell related inflammatory diseases

Trial Profile

A phase I study of KTN-0158 for the treatment of mast cell related inflammatory diseases

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs CDX-0158 (Primary)
  • Indications Cancer; Inflammation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Nov 2015 According to a Kolltan Pharmaceuticals media release, the company plans to file an investigational new drug application (IND) for KTN0158 with the FDA in the Q4 of 2015, followed by the initiation of cancer clinical trials in 2016. The company also expects a second IND filing for KTN0158 for neurofibromatosis 1 (NF1) in 2016.
    • 05 Aug 2015 According to a Kolltan Pharmaceuticals media release, this trial is expected to begin in early 2016.
    • 08 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top